(NASDAQ: VERU) Veru's forecast annual revenue growth rate of -10.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Veru's revenue in 2024 is $13,479,224.On average, 5 Wall Street analysts forecast VERU's revenue for 2024 to be $1,952,175,957, with the lowest VERU revenue forecast at $1,507,754,376, and the highest VERU revenue forecast at $2,781,294,480. On average, 5 Wall Street analysts forecast VERU's revenue for 2025 to be $1,750,751,683, with the lowest VERU revenue forecast at $1,171,071,360, and the highest VERU revenue forecast at $2,839,848,048.
In 2026, VERU is forecast to generate $1,317,455,280 in revenue, with the lowest revenue forecast at $1,171,071,360 and the highest revenue forecast at $1,463,839,200.